Bright Minds Biosciences Inc. (DRUG)

Bright Minds Biosciences Statistics

Total Valuation

DRUG has a market cap or net worth of $456.78 million. The enterprise value is $420.21 million.

Market Cap	456.78M
Enterprise Value	420.21M

Important Dates

The next estimated earnings date is Tuesday, December 30, 2025, before market open.

Earnings Date	Dec 30, 2025
Ex-Dividend Date	n/a

Share Statistics

DRUG has 7.79 million shares outstanding. The number of shares has increased by 49.67% in one year.

Current Share Class	7.79M
Shares Outstanding	7.79M
Shares Change (YoY)	+49.67%
Shares Change (QoQ)	+0.65%
Owned by Insiders (%)	20.40%
Owned by Institutions (%)	37.80%
Float	4.22M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	12.02
P/TBV Ratio	12.02
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 86.56, with a Debt / Equity ratio of 0.00.

Current Ratio	86.56
Quick Ratio	85.39
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-962.44

Financial Efficiency

Return on equity (ROE) is -30.79% and return on invested capital (ROIC) is -18.53%.

Return on Equity (ROE)	-30.79%
Return on Assets (ROA)	-18.31%
Return on Invested Capital (ROIC)	-18.53%
Return on Capital Employed (ROCE)	-16.59%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +37.94% in the last 52 weeks. The beta is -0.33, so DRUG's price volatility has been lower than the market average.

Beta (5Y)	-0.33
52-Week Price Change	+37.94%
50-Day Moving Average	55.76
200-Day Moving Average	39.03
Relative Strength Index (RSI)	51.82
Average Volume (20 Days)	190,606

Short Selling Information

The latest short interest is 233,622, so 3.00% of the outstanding shares have been sold short.

Short Interest	233,622
Short Previous Month	231,038
Short % of Shares Out	3.00%
Short % of Float	5.54%
Short Ratio (days to cover)	1.68

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-6.31M
Pretax Income	-6.54M
Net Income	-6.54M
EBITDA	n/a
EBIT	-6.31M
Earnings Per Share (EPS)	-$1.06

Balance Sheet

The company has $37.68 million in cash and $103,405 in debt, giving a net cash position of $37.57 million or $4.83 per share.

Cash & Cash Equivalents	37.68M
Total Debt	103,405
Net Cash	37.57M
Net Cash Per Share	$4.83
Equity (Book Value)	38.00M
Book Value Per Share	5.36
Working Capital	37.95M

Cash Flow

Operating Cash Flow	-5.78M
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

DRUG does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-49.67%
Shareholder Yield	-49.67%
Earnings Yield	-1.43%
FCF Yield	n/a

Analyst Forecast

The average price target for DRUG is $81.67, which is 41.08% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$81.67
Price Target Difference	41.08%
Analyst Consensus	Strong Buy
Analyst Count	9
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on July 14, 2023. It was a reverse split with a ratio of 1:5.

Last Split Date	Jul 14, 2023
Split Type	Reverse
Split Ratio	1:5

Scores

Altman Z-Score	n/a
Piotroski F-Score	2